RT Journal Article
T1 Evaluation of the gut microbiota after metformin intervention in children with obesity: A metagenomic study of a randomized controlled trial
A1 Pastor-Villaescusa, Belén
A1 Plaza-Díaz, Julio
A1 Egea-Zorrilla, Alejandro
A1 Leis, Rosaura
A1 Bueno, Gloria
A1 Hoyos, Raúl
A1 Vázquez-Cobela, Rocío
A1 Latorre, Miriam
A1 Cañete, María Dolores
A1 Caballero-Villarraso, Javier
A1 Gil, Ángel
A1 Cañete, Ramón
A1 Aguilera, Concepción María
K1 Metformin
K1 Microbiota
K1 Children population
K1 Pubertal stage
K1 Obesity
K1 Healthy lifestyle
K1 Gut microbiota
K1 Verrucomicrobia
K1 Actinobacteria
K1 Bacteroidetes
K1 Firmicutes
K1 Bacillus
K1 Metformina
K1 Niño
K1 Obesidad
K1 Estilo de vida saludable
K1 Microbioma gastrointestinal
K1 Ensayo clínico controlado aleatorio
AB BackgroundMetformin, a first-line oral antidiabetic agent that has shown promising results in terms of treating childhood and adolescent obesity, might influence the composition of the gut microbiota. We aimed to evaluate whether the gut microbiota of non-diabetic children with obesity changes after a metformin intervention.MethodsThe study was a multicenter and double-blind randomized controlled trial in 160 children with obesity. Children were randomly assigned to receive either metformin (1 g/day) or placebo for 6 months in combination with healthy lifestyle recommendations in both groups. Then, we conducted a metagenomic analysis in a subsample obtained from 33 children (15 metformin, 18 placebo). A linear mixed-effects model (LMM) was used to determine the abundance changes from baseline to six months according to treatment. To analyze the data by clusters, a principal component analysis was performed to understand whether lifestyle habits have a different influence on the microbiota depending on the treatment group.ResultsActinobacteria abundance was higher after placebo treatment compared with metformin. However, the interaction time x treatment just showed a trend to be significant (4.6% to 8.1% after placebo vs. 3.8 % to 2.6 % after metformin treatment, p = 0.055). At genus level, only the abundance of Bacillus was significantly higher after the placebo intervention compared with metformin (2.5% to 5.7% after placebo vs. 1.5 % to 0.8 % after metformin treatment, p = 0.044). Furthermore, different ensembles formed by Firmicutes, Bacteroidetes, and Verrucomicrobia were found according to the interventions under a similar food consumption.ConclusionFurther studies with a large sample size controlled by lifestyle patterns are required in obese children and adolescents to clarify whether metformin might trigger gut microbiota alterations. Trial Registration: Registered on the European Clinical Trials Database (EudraCT, ID: 2010−023061-21) on 14 November 2011.
PB Elsevier Masson SAS
SN 0753-3322
YR 2020
FD 2020-12-24
LK http://hdl.handle.net/10668/4375
UL http://hdl.handle.net/10668/4375
LA en
NO Pastor-Villaescusa B, Plaza-Díaz J, Egea-Zorrilla A, Leis R, Bueno G, Hoyos R, et al. Evaluation of the gut microbiota after metformin intervention in children with obesity: A metagenomic study of a randomized controlled trial. Biomed Pharmacother. 2020 Dic;134:111117.
DS RISalud
RD Apr 9, 2025